Cargando…

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma

This observational study evaluated the treatment outcomes of clinical factors on the patients with lung adenocarcinoma with epidermal growth factor receptor mutations who received tyrosine kinase inhibitors as first-line treatment. Patients with stage IIIb or IV lung adenocarcinoma with mutated epid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chi-Cheng, Lin, Chih-Bin, Chu, Sung-Chao, Huang, Wei-Han, Lee, Jen-Jyh, Yang, Gee-Gwo, Wang, Tso-Fu, Wu, Yi-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373628/ https://www.ncbi.nlm.nih.gov/pubmed/32702917 http://dx.doi.org/10.1097/MD.0000000000021275

Ejemplares similares

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments
por: Zhao, Xiayan, et al.
Publicado: (2020)

Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report
por: Liu, Jing, et al.
Publicado: (2021)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

The combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients with resected breast cancer
por: Deng, Yunfu, et al.
Publicado: (2020)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
por: Zhang, Yan, et al.
Publicado: (2018)

Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer
por: Zhao, Guanghui, et al.
Publicado: (2020)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in non-small cell lung cancer
por: Bayraktaroglu, Mesut, et al.
Publicado: (2023)

Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study
por: Tseng, Li-Chuan, et al.
Publicado: (2020)

Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis: A case report
por: Liu, Ning, et al.
Publicado: (2021)

Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis
por: He, Canfeng, et al.
Publicado: (2021)

Correlation between neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and postoperative cognitive dysfunction in elderly patients with esophageal cancer
por: Zhao, Jie, et al.
Publicado: (2023)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
por: Acikgoz, Ozgur, et al.
Publicado: (2021)

Prognostic significance of platelet lymphocyte ratio in patients with melanoma: A meta-analysis
por: Wang, Enwen, et al.
Publicado: (2021)

Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer: A propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review
por: Falcone, Rosa, et al.
Publicado: (2018)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy
por: Ke, Te-Min, et al.
Publicado: (2020)

Negative Impact of Preoperative Platelet-Lymphocyte Ratio on Outcome After Hepatic Resection for Intrahepatic Cholangiocarcinoma
por: Chen, Qing, et al.
Publicado: (2015)

Platelet-to-lymphocyte ratio as a potential prognostic factor in nasopharyngeal carcinoma: A meta-analysis
por: Cen, Rui-Xiang, et al.
Publicado: (2019)

Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte
por: Chen, Liang, et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
por: Kutlu, Yasin, et al.
Publicado: (2023)

The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma
por: de Biase, Dario, et al.
Publicado: (2017)

Exploration of genes and tumor infiltrating lymphocytes in female lung adenocarcinoma microenvironment that predicted prognosis
por: Wang, Lijun, et al.
Publicado: (2021)

Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018)

Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study
por: Ni, Yang, et al.
Publicado: (2016)

The value of hemoglobin-to-red blood cell distribution width ratio (Hb/RDW), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) for the diagnosis of nasopharyngeal cancer
por: Lin, Zhongyuan, et al.
Publicado: (2021)

Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer
por: Ge, Li, et al.
Publicado: (2017)

Prognostic value of platelet-to-lymphocyte ratio in neoadjuvant chemotherapy for solid tumors: A PRISMA-compliant meta-analysis
por: Long, Yuming, et al.
Publicado: (2021)

Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma
por: Carretero-González, Alberto, et al.
Publicado: (2019)

Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer
por: Huang, Qing, et al.
Publicado: (2020)

Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report
por: Ma, Chunhua, et al.
Publicado: (2020)

Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent (177)Lu–PSMA-617
por: Şahin, Elif, et al.
Publicado: (2023)

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
por: Yuan, Jin-Qiu, et al.
Publicado: (2017)

Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report
por: Dong, Min, et al.
Publicado: (2016)

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
por: Meng, Xiangjiao, et al.
Publicado: (2015)

Percentage change of primary tumor on (18)F-FDG PET/CT as a prognostic factor for invasive ductal breast cancer with axillary lymph node metastasis: Comparison with MRI
por: Yoo, Jang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hqms1adjugvkegt49lk3kjunbg